Ranbaxy shrugs off US lawsuit settlement; ends up 4%

Ranbaxy Labs shares recovered from early losses and ended up 3.6 percent on NSE on Tuesday. The company has agreed to settle all alleged civil violations with the US and its US arm is also pleading guilty to criminal charges related to Food, Drugs act.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney Tech Control
moneycontrol.com

Home » News » Business

May 15, 2013, 08.44 AM | Source: Moneycontrol.com

Ranbaxy shrugs off US lawsuit settlement; ends up 4%

Ranbaxy Labs shares recovered from early losses and ended up 3.6 percent on NSE on Tuesday. The company has agreed to settle all alleged civil violations with the US and its US arm is also pleading guilty to criminal charges related to Food, Drugs act.

Like this story, share it with millions of investors on M3

Ranbaxy shrugs off US lawsuit settlement; ends up 4%

Ranbaxy Labs shares recovered from early losses and ended up 3.6 percent on NSE on Tuesday. The company has agreed to settle all alleged civil violations with the US and its US arm is also pleading guilty to criminal charges related to Food, Drugs act.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Shares of pharma major Ranbaxy shrugged off early losses and ended up 3.6 percent at Rs 455.65 on NSE on Tuesday after analysts said the settlement of the US lawsuit now cleared a big overhang on the stock.

The company, owned by Japan's Daiichi Sankyo, said late on Monday that it and its affiliates have agreed to settle all alleged civil violations of the False Claims Act with the US and the company's US subsidiary is pleading guilty to criminal charges related to violation of the Food, Drugs and Cosmetics Act and other criminal statutes.

Ranbaxy will pay USD 500 million for both the civil and criminal settlements, which it had already made a provision for in FY2012, and so the payment won't have any impact on its earnings this year.

In 2008, the US FDA had banned Ranbaxy from exporting 30 drugs from its facilities in Dewas, Madhya Pradesh and Paonta Sahib, Himachal Pradesh and also stopped marketing approvals for new ones following quality control and data reporting issues.

The company entered into a consent decree with the US Food and Drugs Administration in 2011, under which it committed to further strengthen procedures and policies and to ensure data integrity and to comply with Current Good Manufacturing Practice.

Also Read: Ranbaxy whistleblower Thakur richer by Rs 266cr; speaks out

Buy, Hold, Sell ? Hear it first on M3
Ranbaxy shrugs off US lawsuit settlement; ends up 4%

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login